A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Cogent Biosciences, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 38,200 shares of COGT stock, worth $346,856. This represents 0.0% of its overall portfolio holdings.

Number of Shares
38,200
Previous 36,600 4.37%
Holding current value
$346,856
Previous $308,000 33.77%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$8.24 - $11.48 $4,968 - $6,922
603 Added 6.67%
9,647 $104,000
Q2 2024

Aug 14, 2024

SELL
$6.01 - $9.04 $738,310 - $1.11 Million
-122,847 Reduced 93.14%
9,044 $76,000
Q1 2024

May 15, 2024

SELL
$4.38 - $9.02 $2.23 Million - $4.59 Million
-508,880 Reduced 79.42%
131,891 $886,000
Q4 2023

Feb 14, 2024

BUY
$4.06 - $10.08 $2.36 Million - $5.85 Million
580,166 Added 957.29%
640,771 $3.77 Million
Q3 2023

Nov 14, 2023

SELL
$9.69 - $13.34 $718,629 - $989,321
-74,162 Reduced 55.03%
60,605 $590,000
Q2 2023

Aug 14, 2023

SELL
$9.85 - $13.24 $11.4 Million - $15.4 Million
-1,161,005 Reduced 89.6%
134,767 $1.6 Million
Q1 2023

May 15, 2023

SELL
$10.04 - $15.5 $5.61 Million - $8.66 Million
-558,548 Reduced 30.12%
1,295,772 $14 Million
Q4 2022

Feb 14, 2023

BUY
$10.65 - $14.84 $5.56 Million - $7.75 Million
522,040 Added 39.18%
1,854,320 $21.4 Million
Q3 2022

Nov 14, 2022

BUY
$9.39 - $16.99 $2.45 Million - $4.43 Million
260,766 Added 24.34%
1,332,280 $19.9 Million
Q2 2022

Aug 15, 2022

BUY
$3.92 - $9.73 $3.94 Million - $9.79 Million
1,006,013 Added 1535.87%
1,071,514 $9.67 Million
Q1 2022

May 16, 2022

BUY
$5.31 - $8.7 $271,664 - $445,100
51,161 Added 356.77%
65,501 $491,000
Q3 2021

Nov 15, 2021

SELL
$5.99 - $9.14 $7.72 Million - $11.8 Million
-1,289,319 Reduced 98.9%
14,340 $121,000
Q1 2021

May 17, 2021

BUY
$7.47 - $12.34 $3.34 Million - $5.51 Million
446,717 Added 52.13%
1,303,659 $11.1 Million
Q4 2020

Feb 16, 2021

BUY
$9.04 - $13.01 $7.75 Million - $11.1 Million
856,942 New
856,942 $9.62 Million

Others Institutions Holding COGT

About Cogent Biosciences, Inc.


  • Ticker COGT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 65,758,300
  • Market Cap $597M
  • Description
  • Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...
More about COGT
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.